492 related articles for article (PubMed ID: 31319999)
21. Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report.
Falk M; Schatz S; Reich FPM; Schmidt S; Galster M; Tiemann M; Ficker JH; Brueckl WM
Curr Oncol; 2023 Sep; 30(10):8865-8871. PubMed ID: 37887540
[TBL] [Abstract][Full Text] [Related]
22. Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.
Buder A; Heitzer E; Waldispühl-Geigl J; Weber S; Moser T; Hochmair MJ; Hackner K; Errhalt P; Setinek U; Filipits M
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33919291
[TBL] [Abstract][Full Text] [Related]
23. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.
Vendrell JA; Quantin X; Aussel A; Solassol I; Serre I; Solassol J
Transl Lung Cancer Res; 2021 Nov; 10(11):4084-4094. PubMed ID: 35004240
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
Mondaca S; Lebow ES; Namakydoust A; Razavi P; Reis-Filho JS; Shen R; Offin M; Tu HY; Murciano-Goroff Y; Xu C; Makhnin A; Martinez A; Pavlakis N; Clarke S; Itchins M; Lee A; Rimner A; Gomez D; Rocco G; Chaft JE; Riely GJ; Rudin CM; Jones DR; Li M; Shaffer T; Hosseini SA; Bertucci C; Lim LP; Drilon A; Berger MF; Benayed R; Arcila ME; Isbell JM; Li BT
Lung Cancer; 2021 Sep; 159():66-73. PubMed ID: 34311346
[TBL] [Abstract][Full Text] [Related]
25. Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
Gray JE; Han JY; Telaranta-Keerie A; Huang X; Kohlmann A; Hodge R; Rukazenkov Y; Chmielecki J; Espenschied CR; Lefterova M; Wu YL; Ramalingam SS; Barrett JC; Odegaard JI
J Mol Diagn; 2024 Jan; 26(1):73-84. PubMed ID: 37981090
[TBL] [Abstract][Full Text] [Related]
26. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.
Hua G; Zhang X; Zhang M; Wang Q; Chen X; Yu R; Bao H; Liu J; Wu X; Shao Y; Liang B; Lu K
ESMO Open; 2022 Feb; 7(1):100337. PubMed ID: 35123209
[TBL] [Abstract][Full Text] [Related]
27. Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.
Zhang L; Coffin J; Formenti K; Chu Q; Izevbaye I
BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35091437
[TBL] [Abstract][Full Text] [Related]
28. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.
Lindquist KE; Karlsson A; Levéen P; Brunnström H; Reuterswärd C; Holm K; Jönsson M; Annersten K; Rosengren F; Jirström K; Kosieradzki J; Ek L; Borg Å; Planck M; Jönsson G; Staaf J
Oncotarget; 2017 May; 8(21):34796-34810. PubMed ID: 28415793
[TBL] [Abstract][Full Text] [Related]
29. Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis.
Fan Y; Wang X; Yang C; Chen H; Wang H; Wang X; Hou S; Wang L; Luo Y; Sha X; Yang H; Yu T; Jiang X
J Magn Reson Imaging; 2023 Dec; 58(6):1838-1847. PubMed ID: 37144750
[TBL] [Abstract][Full Text] [Related]
30. ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer.
Hou H; Sun D; Zhang C; Liu D; Zhang X
Thorac Cancer; 2021 Mar; 12(6):962-969. PubMed ID: 33506568
[TBL] [Abstract][Full Text] [Related]
31. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.
Schwaederlé MC; Patel SP; Husain H; Ikeda M; Lanman RB; Banks KC; Talasaz A; Bazhenova L; Kurzrock R
Clin Cancer Res; 2017 Sep; 23(17):5101-5111. PubMed ID: 28539465
[No Abstract] [Full Text] [Related]
32. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.
Lee KWC; Li MSC; Gai W; Lau YM; Chan AKC; Chan OSH; Lee CK; Yeung RMW; Fung SYH; Cheung WF; Chan VW; Leung L; Kam KNP; Mok TSK
JAMA Oncol; 2023 Feb; 9(2):261-265. PubMed ID: 36580285
[TBL] [Abstract][Full Text] [Related]
33. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
Ang YLE; Zhao X; Reungwetwattana T; Cho BC; Liao BC; Yeung R; Loong HH; Kim DW; Yang JC; Lim SM; Ahn MJ; Lee SH; Suwatanapongched T; Kongchauy K; Ou Q; Yu R; Tai BC; Goh BC; Mok TSK; Soo RA
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894366
[TBL] [Abstract][Full Text] [Related]
34. Future Perspectives in Detecting
Ferreira D; Miranda J; Martins-Lopes P; Adega F; Chaves R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916986
[TBL] [Abstract][Full Text] [Related]
35. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.
Chen N; Tyler LC; Le AT; Welsh EA; Fang B; Elliott A; Davies KD; Danhorn T; Riely GJ; Ladanyi M; Haura EB; Doebele RC
Mol Cancer Ther; 2024 Jan; 23(1):92-105. PubMed ID: 37748191
[TBL] [Abstract][Full Text] [Related]
36. Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
Bonanno L; Pavan A; Ferro A; Calvetti L; Frega S; Pasello G; Aprile G; Guarneri V; Conte P;
Oncologist; 2020 Dec; 25(12):e1996-e2005. PubMed ID: 32557976
[TBL] [Abstract][Full Text] [Related]
37. ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
Itchins M; Lau B; Hudson AL; Westman H; Xia CY; Hayes SA; Howell VM; Rodriguez M; Cooper WA; Wei H; Buckland M; Li BT; Li M; Rathi V; Fox SB; Gill AJ; Clarke SJ; Boyer MJ; Pavlakis N
Oncologist; 2020 Aug; 25(8):641-649. PubMed ID: 32558067
[TBL] [Abstract][Full Text] [Related]
38. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon JJ; Simmons AD; Lovejoy AF; Esfahani MS; Newman AM; Haringsma HJ; Kurtz DM; Stehr H; Scherer F; Karlovich CA; Harding TC; Durkin KA; Otterson GA; Purcell WT; Camidge DR; Goldman JW; Sequist LV; Piotrowska Z; Wakelee HA; Neal JW; Alizadeh AA; Diehn M
Nat Commun; 2016 Jun; 7():11815. PubMed ID: 27283993
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.
Chen Y; Chen Z; Chen R; Fang C; Zhang C; Ji M; Yang X
Future Oncol; 2022 May; 18(14):1757-1775. PubMed ID: 35232247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
